Sorrento Therapeutics
San Diego, California, United States · Founded 2006
About Sorrento Therapeutics
Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.
Company Facts
- Founded: 2006
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $264.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2019)
- Ticker: nasdaq:SRNE
- Website: sorrentotherapeutics.com
- Phone: (858) 210-3759
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sorrento-therapeutics-2246255 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.